InGel Therapeutics

Allston, MA · Founded 2022 · Privately Held (backing)

Developer of engineered cell therapy designed to target neuroprotective pathways to treat retinal degeneration. InGel Therapeutics is based in Allston, MA and was founded in 2022. It was valued at $17 million at its seed round in Jul 2024, the last priced event on record. It has raised $10.8 million across 1 recorded round; the latest was a $350,000 seed round in Jul 2022.

PMV mark · valuation
$17.0M
Oct 2026
Priced at
its seed round
Jul 2024
Total raised
$10.8M
Last round
Seed Round
Jul 2022

Who backs InGel Therapeutics?

16 investors
InvestorType
Alumni VenturesVenture capital
Service Provider CapitalVenture capital
Calm VenturesVenture capital
Endless Frontier Labs—
Harvard Innovation Launch LabOther
NFXVenture capital
SBXiVenture capital
MassVenturesOther
ZAKA VCVenture capital
The Venture CollectiveVenture capital
+ 6 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

InGel Therapeutics investors

16 investors are on record for InGel Therapeutics, including Alumni Ventures, Service Provider Capital, Calm Ventures and Endless Frontier Labs. By type, the record holds 7 venture capital firms. The seed round in Jul 2022 drew 4 investors.

Free account
More of InGel Therapeutics with a free account
  • ·The complete investor list: 16 names
  • ·Watch InGel Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 16 firms already write checks for companies like InGel Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View